Regulus renews Sanofi microRNA pact to focus on orphan, cancer treatments

California microRNA specialist Regulus Therapeutics ($RGLS) renewed an almost-four-year-old partnership with Sanofi ($SNY) to help develop its RNA programs further for orphan and oncology purposes, collecting a $10 million equity investment in the process. Of particular interest to Sanofi is Regulus' microRNA-21 candidate for the orphan kidney-affecting Alport syndrome and a proof-of-concept cancer treatment. Back in 2010, Sanofi hooked up with Regulus--a spinoff of Alnylam ($ALNY) and Isis ($ISIS)--for up to $750 million. The two companies are using the discovery and delivery techniques developed by Alnylam and Isis to, they hope, finally make RNA drugs effective. Release